GCP;GIG;Folate hydrolase;Glutamate carboxypeptidase;NAALAD;FGCP;FOLH;GCP2;GCPII;NAALAD1;NAALAdase;PSM;PSMA;mGCP;FOLH1;Cell growth-inhibiting gene 27 protein;Folate hydrolase 1;Glutamate carboxypeptidase 2;NAALADase I;N-acetylated alpha-linked acidic dipeptidase 1|cell growth-inhibiting protein 27|folate hydrolase 1|folylpoly-gamma-glutamate carboxypep;GIG27;FGCP;FOLH;GCP2;GCPII;NAALAD1;NAALAdase;PSM;PSMA;mGCP;FOLH1

Mammalian

Lys44-Ala750

Q04609

Human

102.6 kDa

100-110 kDa

C-Fc

Not validated for activity

> 90% as determined by reducing SDS-PAGE.

< 1.0 EU/mg of the protein as determined by the LAL method

Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

This product is provided as lyophilized powder which is shipped with ice packs.

Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Glutamate carboxypeptidase 2 , also known as Glutamate carboxypeptidase II , Membrane glutamate carboxypeptidase , Prostate-specific membrane antigen , GCPII , PSMA , FOLH1 , and NAALAD1 , is a single-pass type II membrane protein which belongs to thepeptidase M28 family and M28B subfamily. FOLH1 is highly expressed in prostate epithelium. It is detected in urinary bladder , kidney , testis , ovary , fallopian tube , breast , adrenal gland , liver , esophagus , stomach , small intestine , colon , brain (at protein level) , and the capillary endothelium of a variety of tumors. FOLH1 has both folate hydrolase and N-acetylated alpha linked acidic dipeptidase (NAALADase) activity. It has a preference for tri-alpha-glutamate peptides. Genetic variation in FOLH1 may be associated with low folate levels and consequent hyperhomocysteinemia. This condition can result in increased risk of cardiovascular disease , neural tube defects , and cognitive deficits. FOLH1 also shows a promising role in directed imaging and therapy of recurrent or metastatic disease.